Search Result

Results for "

Lyn kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Apoptosis (18) Aurora Kinase (1) Autophagy (7) Bcr-Abl (10) BCRP (1) Btk (5) c-Kit (1) CDK (1) COX (1) Cyclin G-associated Kinase (GAK) (1) Drug Isomer (1) EGFR (1) Endogenous Metabolite (3) Ephrin Receptor (1) ERK (2) FAK (1) FGFR (6) FLT3 (2) IGF-1R (1) Interleukin Related (3) IRAK (1) Isotope-Labeled Compounds (2) JNK (1) Lipoxygenase (1) MAP4K (1) Molecular Glues (1) p38 MAPK (1) PDGFR (7) PROTACs (1) Raf (2) Reference Standards (7) Salt-inducible Kinase (SIK) (1) Src (33) STAT (1) Syk (6) ULK (5) VEGFR (7) Wee1 (1)
By Research Areas:	Cancer (38) Endocrinology (1) Inflammation/Immunology (17) Metabolic Disease (3) Neurological Disease (4)
Click Chemistry:	PROTAC Synthesis (1)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-10234

Saracatinib Maximum Cited Publications 39 Publications Verification AZD0530	Src Autophagy	Cancer
Saracatinib (AZD0530) is a potent Src family inhibitor with IC₅₀s of 2.7 to 11 nM for c-Src, Lck, c-YES, *Lyn, Fyn, Fgr, and Blk. Saracatinib shows high selectivity over other tyrosine kinases* .

HY-12067

R406 35+ Cited Publications	Syk FLT3 Apoptosis	Inflammation/Immunology Cancer
R406 is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a K_i of 30 nM, potently inhibits Syk kinase activity in vitro with an IC₅₀ of 41 nM, measured at an ATP concentration corresponding to its K_m value. R406 reduces immune complex-mediated inflammation . R406 also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM) .

HY-B0789

SU6656 20+ Cited Publications	Src FAK Akt	Cancer
SU6656 is a Src family kinases inhibitor with IC₅₀s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.

HY-50868

Bafetinib 10+ Cited Publications INNO-406; NS-187	Bcr-Abl Src Apoptosis	Cancer
Bafetinib is an orally active *Lyn/Bcr-Abl* tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph ⁺ leukemia cells. Bafetinib has antitumor activity .

HY-112852

TL02-59 5+ Cited Publications	Src Apoptosis	Cancer
TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC₅₀ of 0.03 nM. TL02-59 inhibits *Lyn* and Hck with IC₅₀s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth .

HY-101923

LYN-1604 5+ Cited Publications	ULK Autophagy Apoptosis	Cancer
LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

HY-15764A

A 419259 trihydrochloride 5+ Cited Publications RK 20449 trihydrochloride	Src Apoptosis	Cancer
A 419259 trihydrochloride is a Src family kinases inhibitor with IC₅₀s of 9 nM, 3 nM and 3 nM for Src, Lck and *Lyn*, respectively .

HY-122113

PD173952 1 Publications Verification	Src Bcr-Abl Apoptosis Wee1	Cancer
PD173952 is a tyrosine kinases inhibitor with IC₅₀s of 0.3, 1.7 and 6.6 nM against *Lyn, Abl* and Csk, respectively. PD173952 is also a potent Myt1 kinase inhibitor with a K_i of 8.1 nM. PD173952 induces apoptosis .

HY-11108

R406 free base 35+ Cited Publications	Syk FLT3 Apoptosis	Inflammation/Immunology Cancer
R406 free base is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a K_i of 30 nM, potently inhibits Syk kinase activity in vitro with an IC₅₀ of 41 nM, measured at an ATP concentration corresponding to its K_m value. R406 free base reduces immune complex-mediated inflammation . R406 free base also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM) .

HY-59047

Tolimidone 4 Publications Verification MLR-1023	Src	Metabolic Disease
Tolimidone is a potent and selective allosteric activator of **Lyn kinase with an EC₅₀** of 63 nM.

HY-101923B

LYN-1604 dihydrochloride 5+ Cited Publications	ULK Autophagy Apoptosis	Cancer
LYN-1604 dihydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

HY-12072

Lck Inhibitor 3 Publications Verification	Src	Inflammation/Immunology
Lck Inhibitor is a potent, orally active Lck (lymphocyte specific kinase) inhibitor with IC₅₀s of 7, 2.1, 4.2 and 200 nM for Lck, Lyn, Src and Syk kinases, respectively. Lck Inhibitor shows >1000-fold selectivity for Lck over MAPK, CDK and RSK family representatives. Lck Inhibitor inhibits T cell proliferation and in vivo models of arthritis .

HY-P1111

Lyn peptide inhibitor	Src Interleukin Related	Inflammation/Immunology
Lyn peptide inhibitor (YGYRLRRKWEEKIPNP-NH₂) is a potent, cell-permeable *Lyn* kinase inhibitor that inhibits *Lyn*-coupled signaling pathways associated with the IL-5 receptor while preserving the integrity of other signals. Lyn peptide inhibitor blocks the activation of Lyn and inhibits the binding of Lyn tyrosine kinase to the βc subunit of the IL-3/GM-CSF/IL-5 receptor. Lyn peptide inhibitor can be used in the research of eosinophilic diseases such as asthma and allergy .

HY-15749

XL228 4 Publications Verification	Aurora Kinase Bcr-Abl IGF-1R Src	Endocrinology Cancer
XL228 is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src and *Lyn*, respectively.

HY-137342

SB1-G-187	PROTACs Src IRAK Bcr-Abl MAP4K Cyclin G-associated Kinase (GAK) CDK	Cancer
SB1-G-187 is a multi-target kinase PROTAC degrader with activity against various kinases including GCK, YES1, IRAK1 and *LYN. SB1-G-187 induces degradation of target kinases* via a p97-dependent pathway, and forms ternary complexes with CRBN and specific functional kinases. SB1-G-187 can be used in tumor-related research. (Pink: multi-target kinase ligand (HY-125142); Blue: CRBN ligand (HY-A0003); Black: linker) .

HY-118144

PD166326	Src Bcr-Abl p38 MAPK	Cancer
PD166326 is an orally active tyrosine kinase inhibitor with a IC₅₀ of 8 nM against abl tyrosine kinase and a IC₅₀ of 6 nM against src tyrosine kinase. PD166326 blocks Bcr/Abl kinase activity. PD166326 inhibits Bcr/Abl-dependent proliferation and cell cycle progression. PD166326 reduces peripheral blood granulocytosis, alleviates splenomegaly and prolongs survival in a mouse model of chronic myeloid leukemia. PD166326 can be used in research related to chronic myeloid leukemia .

HY-12039

Lyn-IN-1 Bafetinib analog	Bcr-Abl	Cancer
Lyn-IN-1 (Bafetinib analog) is a *Lyn* kinase inhibitor for the study of thrombocytopenia .

HY-10644

Lck inhibitor 2	Src	Inflammation/Immunology
Lck inhibitor 2 is a multi-target tyrosine kinase inhibitor with IC50s of 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively.

HY-10185

TG 100572 Hydrochloride 3 Publications Verification	Src VEGFR FGFR PDGFR	Inflammation/Immunology
TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-100338

CNX-500	Btk	Cancer
CNX-500 is a probe consisting of a covalent Btk inhibitor (CC-292) chemically linked to biotin. CNX-500 retains inhibitory activity against Btk (IC₅₀ of 0.5 nM) and the ability to form a covalent bond with Btk. CNX-500 has low inhibitory effects on kinase epidermal growth factor receptor, and upstream Src-family kinases including Syk and Lyn .

HY-160167

Birelentinib DZD8586	Src Btk	Inflammation/Immunology Cancer
Birelentinib (DZD8586) is an orally effective, selective, non-covalent inhibitor targeting *LYN* tyrosine kinase and BTK tyrosine kinase, capable of penetrating the blood-brain barrier. Birelentinib exhibits concentration-dependent antiproliferative effects in RI-1 cells and diffuse large B-cell lymphoma (DLBCL) cell lines carrying BTK resistance mutations (such as C481X, V416L, etc.). Birelentinib blocks both BTK-dependent and independent signaling of the B-cell receptor (BCR), thereby inhibiting tumor cell proliferation and inducing cell death. Birelentinib can be used in research to overcome resistance to existing covalent and non-covalent BTK inhibitors in B-cell non-Hodgkin lymphoma (B-NHL) .

HY-153830

LacCer (d18:1/16:0) C16 Lactosylceramide (d18:1/16:0)	Endogenous Metabolite	Neurological Disease Metabolic Disease
LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0)) is an endogenous bioactive sphingolipid that can form membrane microdomains with *Lyn* kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). The levels of LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. In a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder), the expression of LacCer (d18:1/16:0) is also upregulated. LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .

HY-12291

HG6-64-1 HMSL 10017-101-1	Raf Apoptosis	Cancer
HG6-64-1 (HMSL 10017-101-1) is a B-raf kinase modulator.HG6-64-1 modulates B-raf kinase activity, including the V600E mutant form and the drug-resistant gatekeeper mutation T529I. HG6-64-1 is a germinal center kinase inhibitor. HG6-64-1 induces cell cycle arrest and apoptosis. HG6-64-1 can be used for the research of diffuse large B-cell lymphoma (DLBCL) .

HY-10186

TG 100801 1 Publications Verification	VEGFR FGFR PDGFR Src	Cancer
TG 100801 is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, *Lyn, Src, Yes*, respectively.

HY-123450

S116836	Bcr-Abl Apoptosis PDGFR	Cancer
S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies . S116836 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-12736A

GSK143 dihydrochloride 1 Publications Verification	Syk ERK	Inflammation/Immunology Cancer
GSK143 dihydrochloride is an orally active and highly selective *spleen tyrosine kinase* (SYK) inhibitor with a pIC₅₀ of 7.5. GSK143 dihydrochloride inhibits phosphorylated Erk (pErk: pIC₅₀**=7.1) . GSK143 dihydrochloride reduces inflammation and prevents recruitment of immune cells in the intestinal muscularis in mice .

HY-10234A

Saracatinib difumarate Maximum Cited Publications 39 Publications Verification AZD0530 difumarate	Src	Cancer
Saracatinib (AZD0530) difumarate is a potent Src inhibitor with IC50 values of 2.7-11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr and Blk, and is selective for other tyrosine kinases. .

HY-10184

TG 100572	Src VEGFR PDGFR FGFR	Cancer
TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-113509B

15(R)-Lipoxin A4 15-epi-LXA4	STAT COX Lipoxygenase JNK Endogenous Metabolite	Neurological Disease Inflammation/Immunology
15 (R)-Lipoxin A4 (15-epi-LXA4) is a specialized pro-resolving mediator and an acetylated derivative of COX2. 15 (R)-Lipoxin A4 is present in neurons. 15 (R)-Lipoxin A4 induces the SPM synthases ALOX12 and ALOX15, as well as the pro-resolving receptor ALX. 15 (R)-Lipoxin A4 inhibits protein kinases, including JNK1/2/3, *Lyn, STAT-3* and STAT-6. 15 (R)-Lipoxin A4 enhances the release of pro-resolving mediators. 15 (R)-Lipoxin A4 alleviates the pro-inflammatory phenotype of tendon-derived stromal cells. 15 (R)-Lipoxin A4 promotes the resolution of neuroinflammation. 15 (R)-Lipoxin A4 is applicable to research related to achilles tendinitis, achilles tendon rupture and Alzheimer’s disease .

HY-111781

Civorebrutinib WS-413	Btk	Cancer
Civorebrutinib (WS-413) is a selective, orally active BTK and TEC inhibitor with an IC₅₀ of <100 nM for both targets. Civorebrutinib inhibits B cell activation. Civorebrutinib significantly suppresses the in vivo growth of diffuse large B-cell lymphoma cells. Civorebrutinib can be used for the research of diffuse large B-cell lymphoma .

HY-175437

MRT-7612	Molecular Glues Src Bcr-Abl	Inflammation/Immunology Cancer
MRT-7612 (Compound 4) is a cereblon-based tyrosine kinases molecular glue degrader. MRT-7612 significantly induces HCK and *LYN* degradation, with week efficacy on LCK. MRT-7612 can be used for cancers like chronic myeloid leukemia, autoimmune and chronic inflammatory diseases research .

HY-10187

TG 100801 Hydrochloride	VEGFR FGFR PDGFR Src	Cancer
TG 100801 Hydrochloride is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-18010

PCI 29732 3 Publications Verification	Btk BCRP	Inflammation/Immunology
PCI 29732 is a potent, orally active, reversible BTK inhibitor with K_i ^app values of 8.2, 4.6, and 2.5 nM for BTK, Lck and Lyn, respectively. PCI 29732 shows only modest inhibitory activity against Itk, another Tec family kinase. PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 .

HY-12736

GSK143	Syk ERK	Inflammation/Immunology Cancer
GSK143 is an orally active and highly selective *spleen tyrosine kinase* (SYK) inhibitor with a pIC₅₀ of 7.5. GSK143 inhibits phosphorylated Erk (pErk: pIC₅₀**=7.1) . GSK143 reduces inflammation and prevents recruitment of immune cells in the intestinal muscularis in mice .

HY-P1111A

Lyn peptide inhibitor TFA	Src Interleukin Related	Inflammation/Immunology
Lyn peptide inhibitor TFA is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor TFA blocks Lyn activation and inhibits the binding of **Lyn tyrosine kinase** to βc subunit of IL-3/GM-CSF/IL-5 receptors. Lyn peptide inhibitor TFA can be used for study of asthma, allergic, and other eosinophilic disorders .

HY-101923A

LYN-1604 hydrochloride	ULK Autophagy Apoptosis	Cancer
LYN-1604 hydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

HY-150026

*Multi-kinase-IN-2*	VEGFR PDGFR FGFR c-Kit Akt Src Apoptosis	Cancer
Multi-kinase-IN-2 (compound 7h) is an orally active and potent angiokinase inhibitor. Multi-kinase-IN-2 exhibits excellent inhibitory activity against angiokinases including VEGFR-1/2/3, PDGFRα/β, and FGFR-1, as well as *LYN* and c-KIT kinases. Multi-kinase-IN-2 significantly attenuates phosphorylation of AKT and ERK proteins. Multi-kinase-IN-2 induces cell apoptosis. Multi-kinase-IN-2 shows anticancer activity .

HY-178014

SIK1-IN-1	Salt-inducible Kinase (SIK) Src	Others
SIK1-IN-1 (Compound 27) is a selective *Salt-inducible kinase* 1 (SIK1) inhibitor with an IC₅₀** of 0.7  nM for SIK1 over SIK2 and SIK3. SIK1-IN-1 has no cytotoxicity against HEK293 cells and PBMCs (maximum concentration of 30 μM). SIK1-IN-1 also has potent inhibitory activities for 392 kinases, in particular tyrosine kinases, such as FGR, HCK and *LYN*) .

HY-112852A

TL02-59 dihydrochloride	Src Apoptosis	Cancer
TL02-59 dihydrochloride is an orally active, selective Src-family kinase Fgr inhibitor with an IC₅₀ of 0.03 nM. TL02-59 dihydrochloride inhibits *Lyn* and Hck with IC₅₀s of 0.1 nM and 160 nM, respectively. TL02-59 dihydrochloride potently suppresses acute myelogenous leukemia (AML) cell growth .

HY-124605

IQS-019	Syk Btk Apoptosis	Cancer
IQS-019 is a B cell receptor (BCR) kinase inhibitor. IQS-019 can inhibit the de-phosphorylation of constitutive and IgM-activated Syk, *Lyn, and Btk. IQS-019 can inhibit cell proliferation, migration and induce apoptosis*. IQS-019 exhibits antitumor activity and can be used for the research of cancer, such as B cell lymphoma .

HY-153830S

LacCer (d18:1/16:0)-d3 C16 Lactosylceramide (d18:1/16:0)-d₃	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease Metabolic Disease
LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0))-d₃ is the deuterium labeled LacCer (d18:1/16:0) (HY-153830). LacCer (d18:1/16:0) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. LacCer (d18:1/16:0) is also upregulated in a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder). LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .

HY-171217

TG-100435	Src Bcr-Abl Ephrin Receptor	Cancer
TG-100435 is a multitargeted, orally active protein tyrosine kinase inhibitor, with K_i of 13 to 64 nM for Src, *Lyn, Abl, Yes, Lck, and EphB4*. TG-100435 plays an important role in cancer research .

HY-10234AR

Saracatinib difumarate (Standard) AZD0530 difumarate (Standard)	Src Reference Standards	Cancer
Saracatinib (difumarate) (Standard) is the analytical standard of Saracatinib (difumarate). This product is intended for research and analytical applications. Saracatinib (AZD0530) difumarate is a potent Src inhibitor with IC50 values of 2.7-11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr and Blk, and is selective for other tyrosine kinases. .

HY-10234R

Saracatinib (Standard) AZD0530 (Standard)	Reference Standards Src Autophagy	Cancer
Saracatinib (Standard) is the analytical standard of Saracatinib. This product is intended for research and analytical applications. Saracatinib (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib shows high selectivity over other tyrosine kinases .

HY-135216

Antiproliferative agent-54	Src VEGFR Raf EGFR	Cancer
Antiproliferative agent-54 (Compound 6z) is the inhibitor for multiple kinases, such as ABL WT, B-RAF, EGFR, HCK, LYN A and SRC with IC₅₀ of 6-50 nM. Antiproliferative agent-54 inhibits proliferation of several cancer cell, inhibits HUVEC and HepG2, with EC₅₀ of 34 and 38 nM. Antiproliferative agent-54 exhibits good pharmacokinetic characteristics in rats .

HY-50868R

Bafetinib (Standard) INNO-406 (Standard); NS-187 (Standard)	Bcr-Abl Src Apoptosis Reference Standards	Cancer
Bafetinib (Standard) is the analytical standard of Bafetinib. This product is intended for research and analytical applications. Bafetinib is an orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph+ leukemia cells. Bafetinib has antitumor activity .

HY-112369

LDDN-0003499	Src Interleukin Related	Neurological Disease Inflammation/Immunology
LDDN-0003499 is a Src family tyrosine kinase inhibitor and anti-inflammatory agent. LDDN-0003499 reduces basal and Aβ-stimulated levels of active, phosphorylated *Lyn* and Src kinases, and attenuates Aβ-stimulated secretion of pro-inflammatory cytokines TNFα and IL-6 in microglial cells. LDDN-0003499 can be used for the research of Alzheimer's disease .

HY-101923R

LYN-1604 (Standard)	Reference Standards ULK Autophagy Apoptosis	Cancer
LYN-1604 (Standard) is the analytical standard of LYN-1604 (HY-101923). This product is intended for research and analytical applications. LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

HY-101923BR

LYN-1604 dihydrochloride (Standard)	Reference Standards ULK Autophagy Apoptosis	Cancer
LYN-1604 dihydrochloride (Standard) is the analytical standard of LYN-1604 dihydrochloride (HY-101923B). This product is intended for research and analytical applications. LYN-1604 dihydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

HY-10644R

Lck inhibitor 2 (Standard)	Reference Standards Src	Inflammation/Immunology
Lck inhibitor 2 (Standard) is the analytical standard of Lck inhibitor 2 (HY-10644). This product is intended for research and analytical applications. Lck inhibitor 2 is a multi-target tyrosine kinase inhibitor with IC₅₀s of 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively.

Cat. No.	Nombre del producto	Target	Research Area

HY-P1111

Lyn peptide inhibitor	Src Interleukin Related	Inflammation/Immunology
Lyn peptide inhibitor (YGYRLRRKWEEKIPNP-NH₂) is a potent, cell-permeable *Lyn* kinase inhibitor that inhibits *Lyn*-coupled signaling pathways associated with the IL-5 receptor while preserving the integrity of other signals. Lyn peptide inhibitor blocks the activation of Lyn and inhibits the binding of Lyn tyrosine kinase to the βc subunit of the IL-3/GM-CSF/IL-5 receptor. Lyn peptide inhibitor can be used in the research of eosinophilic diseases such as asthma and allergy .

HY-P1111A

Lyn peptide inhibitor TFA	Src Interleukin Related	Inflammation/Immunology
Lyn peptide inhibitor TFA is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor TFA blocks Lyn activation and inhibits the binding of **Lyn tyrosine kinase** to βc subunit of IL-3/GM-CSF/IL-5 receptors. Lyn peptide inhibitor TFA can be used for study of asthma, allergic, and other eosinophilic disorders .

Cat. No.	Nombre del producto	Category	Target	Chemical Structure

HY-153830

LacCer (d18:1/16:0) C16 Lactosylceramide (d18:1/16:0)	Microorganisms Saccharides Monosaccharides Source Classification	Endogenous Metabolite
LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0)) is an endogenous bioactive sphingolipid that can form membrane microdomains with *Lyn* kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). The levels of LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. In a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder), the expression of LacCer (d18:1/16:0) is also upregulated. LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .

HY-113509B

15(R)-Lipoxin A4 15-epi-LXA4	Structural Classification Productos naturales Source Classification	STAT COX Lipoxygenase JNK Endogenous Metabolite
15 (R)-Lipoxin A4 (15-epi-LXA4) is a specialized pro-resolving mediator and an acetylated derivative of COX2. 15 (R)-Lipoxin A4 is present in neurons. 15 (R)-Lipoxin A4 induces the SPM synthases ALOX12 and ALOX15, as well as the pro-resolving receptor ALX. 15 (R)-Lipoxin A4 inhibits protein kinases, including JNK1/2/3, *Lyn, STAT-3* and STAT-6. 15 (R)-Lipoxin A4 enhances the release of pro-resolving mediators. 15 (R)-Lipoxin A4 alleviates the pro-inflammatory phenotype of tendon-derived stromal cells. 15 (R)-Lipoxin A4 promotes the resolution of neuroinflammation. 15 (R)-Lipoxin A4 is applicable to research related to achilles tendinitis, achilles tendon rupture and Alzheimer’s disease .

Species:	Human (2)
Tag:	His (1) GST (2)
Source:	Sf9 insect cells (2)

Cat. No.	Compare	Nombre del producto	Species	Source	Image

HY-P706066

	LYNb Protein, Human (Active, sf9, His-GST) Tyrosine-protein kinase Lyn; Lck/Yes-related novel protein tyrosine kinase; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; p53Lyn; p56Lyn; JTK8	Human	Sf9 insect cells

HY-P73283

	LYNa Protein, Human (Active, sf9, GST) Hck-2; JTK8; Tyrosine-protein kinase Lyn	Human	Sf9 insect cells
	Lyn protein is a non-receptor tyrosine protein kinase that centrally mediates signals from diverse cell surface receptors, regulating immune responses, hematopoiesis, and integrin signaling. It acts as a negative or positive regulator depending on the context, affecting B cell responses, differentiation and inflammatory responses. LYNa Protein, Human (Active, sf9, GST) is the recombinant human-derived LYNa protein, expressed by Sf9 insect cells , with N-GST labeled tag.

Compare Products


Products	En stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / En stock - + Añadir al carrito Obtener un presupuesto

Cat. No.	Nombre del producto	Chemical Structure

HY-153830S

LacCer (d18:1/16:0)-d3

LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0))-d₃ is the deuterium labeled LacCer (d18:1/16:0) (HY-153830). LacCer (d18:1/16:0) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. LacCer (d18:1/16:0) is also upregulated in a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder). LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .

HY-112852S

TL02-59-d5
TL02-59-d₅ is the deuterium labeled TL02-59 (HY-112852). TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an ICC₅₀ of 0.03 nM. TL02-59 inhibits Lyn and Hck with ICC₅₀s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth.

Host:	Mouse (3) Rabbit (2)
Reactivity:	Human (5) Rat (2) Mouse (2)
Application:	ICC/IF (2) WB (5) FC (1) ELISA (1)
Isotype:	IgG (1) IgG1 (3)
Conjugation:	Non-conjugated (5)
Clonality:	Monoclonal (3) Recombinant (1)
Modification:	Unmodified (3)

Cat. No.	Compare	Nombre del producto	Application	Reactivity	Image

HY-P80747

	Lyn Antibody (YA707) Lyn; JTK8; Tyrosine-protein kinase Lyn; Lck/Yes-related novel protein tyrosine kinase; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; p53Lyn; p56Lyn	WB	Human
	Lyn Antibody (YA707) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Lyn.

HY-P85265

	Lyn Antibody (YA4957) Lyn; JTK8; Tyrosine-protein kinase Lyn; Lck/Yes-related novel protein tyrosine kinase; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; p53Lyn; p56Lyn	WB, FC	Human
	Lyn Antibody (YA4957) is a Rabbit-derived and non-conjugated recomninant monoclonal antibody, targeting to Lyn.

HY-P80747A

	Lyn Antibody (YA707)(PBS only) Lyn; JTK8; Tyrosine-protein kinase Lyn; Lck/Yes-related novel protein tyrosine kinase; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; p53Lyn; p56Lyn	WB	Human
	Lyn Antibody (YA707) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Lyn.

HY-P85877

	Lyn Antibody (YA5569) Tyrosine-protein kinase Lyn; Lck/Yes-related novel protein tyrosine kinase; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; p53Lyn; p56Lyn;	WB, ICC/IF, ELISA	Human, Mouse, Rat
	Lyn Antibody (YA5569) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Lyn.

HY-P810639

	Phospho-LYN (Tyr397)/LCK (Tyr394)/HCK (Tyr411)/BLK (Tyr389) Antibody (YA9901) Lyn; JTK8; Tyrosine-protein kinase Lyn; Lck/Yes-related novel protein tyrosine kinase; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; p53Lyn; p56Lyn	WB, ICC/IF	Human, Mouse, Rat
	Phospho-LYN (Tyr397)/LCK (Tyr394)/HCK (Tyr411)/BLK (Tyr389) Antibody (YA9901) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-LYN (Tyr397)/LCK (Tyr394)/HCK (Tyr411)/BLK (Tyr389).